S-1/A: Mustang Bio Announces Proposed Public Offering of Common Stock and Warrants

Mustang Bio is offering up to 15,625,000 shares of common stock and accompanying warrants in a public offering to raise capital for working capital, pipeline development, and general corporate purposes.

Summary

• Mustang Bio, a clinical-stage biopharmaceutical company, has filed an amendment to its Form S-1 registration statement for a proposed public offering.
• The offering includes up to 15,625,000 shares of common stock, along with Series A-1, A-2, and A-3 warrants to purchase additional shares.
• Alternatively, the company may offer pre-funded warrants to purchase up to 15,625,000 shares, also with accompanying Series A-1, A-2, and A-3 warrants.
• The assumed combined public offering price is $0.32 per share and accompanying warrants, based on the last reported sale price on April 26, 2024.
• Each warrant has an exercise price of $0.32 per share and varying expiration dates: Series A-1 expires in five years, Series A-2 in twenty-four months, and Series A-3 in nine months from the initial exercise date.
• Pre-funded warrants are offered to purchasers who would exceed beneficial ownership limits (4.99% or 9.99%) and are exercisable at $0.0001 per share.
• The offering also includes 937,500 placement agent warrants to purchase common stock.
• H.C. Wainwright & Co., LLC is acting as the exclusive placement agent.
• The offering is expected to terminate on May 13, 2024.
• Net proceeds will be used for working capital, pipeline development, and general corporate purposes.
• The company is a smaller reporting company and has elected to comply with certain reduced reporting requirements.
• Investing in the company's securities involves risks, as detailed in the prospectus.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the company's financial difficulties, workforce reduction, and Nasdaq compliance issues, despite the potential for pipeline development.

Positives

• The offering aims to provide additional capital for pipeline development activities.
• The company has multiple ongoing Phase 1 clinical trials for its CAR T therapies.
• MB-106 received Orphan Drug Designation for the treatment of Waldenstrom macroglobulinemia (WM).
• MB-106 was granted the Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA for the treatment of relapsed or refractory CD20 positive WM and FL.
• The company has a collaboration with Fred Hutch for a proof-of-concept Phase 1 investigator-sponsored clinical trial evaluating MB-106 in autoimmune diseases.

Negatives

• The company has incurred substantial operating losses since its inception and expects to continue to do so.
• There is substantial doubt regarding the company's ability to continue as a going concern.
• The company recently implemented a significant reduction in workforce (approximately 81%).
• The company does not expect to initiate its pivotal Phase 2 single-arm clinical trial of MB-106 for the treatment of WM trial in 2024.
• The company received a deficiency letter from Nasdaq regarding non-compliance with minimum stockholders' equity requirements.
• The combined offering price per share of common stock and accompanying Warrants and the combined offering price per pre-funded warrant and accompanying Warrants may be at a discount to the current market price of our common stock.

Risks

• The company may not raise the amount of capital it believes is required for its business plans.
• There is no public market for the warrants and pre-funded warrants being offered.
• The market price for the company's common stock has been volatile and may continue to fluctuate.
• The company has broad discretion to determine how to use the funds raised in this offering.
• The company's reliance on third parties for manufacturing increases the risk of insufficient quantities of product candidates.
• The company may be unable to establish agreements with third-party manufacturers or to do so on acceptable terms.
• The company may be required to further revise its business plan and strategy, which may result in curtailing, delaying or discontinuing one or more of its research or development programs or the commercialization of any product candidates.
• The company may be required to seek bankruptcy protection or other alternatives that would likely result in its securityholders losing some or all of their investment in us.

Future Outlook

The company intends to use the net proceeds from this offering for working capital, pipeline development activities and general corporate purposes, but there is no guarantee that the company will be able to execute its business plan.

Industry Context

The document relates to the biopharmaceutical industry, specifically companies focused on cell and gene therapies, particularly CAR T therapies for cancer treatment. The company is attempting to raise capital in a challenging fundraising environment.

Comparison to Industry Standards

• The document does not contain enough information to make a detailed comparison to industry standards.
• The company is developing CAR T therapies, which are being developed by companies such as Novartis (Kymriah), Gilead (Yescarta and Tecartus), and Bristol Myers Squibb (Breyanzi).
• The company is also developing oncolytic virus therapies, which are being developed by companies such as Amgen (Imlygic).

Stakeholder Impact

• Shareholders will experience immediate dilution in the book value per share of the common stock purchased in the offering.
• Employees have been impacted by the recent workforce reduction.
• The company's ability to continue developing its pipeline and potentially bring new therapies to market could impact patients with hematologic cancers, solid tumors and rare genetic diseases.

Next Steps

• The company intends to seek stockholder approval for the issuance of shares of common stock issuable upon exercise of the Warrants.
• The company intends to submit a Compliance Plan to Nasdaq on or before April 29, 2024.
• The company and uBriGene will continue to be actively engaged with CFIUS to obtain clearance for the Transaction.

Key Dates

Keywords

public offering, common stock, warrants, pre-funded warrants, MBIO, capital raise, biopharmaceutical, CAR T therapy, clinical trials, FDA, glioblastoma, hematologic malignancies, oncology